Boehringer Ingelheim

About the Boehringer Ingelheim group of companies

Boehringer Ingelheim was founded in 1885 in Ingelheim, Germany. It is a research-driven company dedicated to researching and developing, manufacturing and marketing pharmaceuticals that improve health and quality of life.

The company’s products have long been successful in the treatment of respiratory, cardiovascular, central nervous system, urological and viral disorders. In addition, the company has successfully advanced its research in thrombo-embolic, cardio-metabolic and oncological diseases. Moreover, the Consumer Health Care products (CHC) are a core business sector within the corporation, covering therapeutic needs in cough and cold, gastrointestinal disorders, cardiovascular prevention and oral care and offering food supplements.

With more than 41.500 employees in 142 affiliated companies worldwide, Boehringer Ingelheim celebrates its 125th jubilee this year and stays dedicated to its aim: to provide more health to patients all over the world.

Boehringer Ingelheim
Year of establishment: 1885

ABOUT Boehringer Ingelheim Ellas

Boehringer Ingelheim Ellas Single Member SA was founded in 1966.

In 1975, a 7.800 m2 production Plant was built in the area of Koropi, setting new standards in the country’s industrial sector.  The plant was awarded the 1st Prize of the Ministry of Culture for harmonious adaptation of industrial facilities to the natural environment.

Being the only multinational pharmaceutical company with manufacturing facilities in Greece, Boehringer Ingelheim Ellas Single Member SA has become a strong player in the Greek industry, not only as a result of the provision of pharmaceuticals to the domestic market, but also due to its exports activity.

The company’s plant produces pharmaceuticals for export to over 45 countries of Eastern Europe, the Balkan, Asia, Northern Africa and the Middle East, and income from exports represents 53% of the company’s total turnover.

The company’s export activity is of great significance as it represents 1% of the total exports income of Greece!

Boehringer Ingelheim Ellas Single Member SA has a work force of 390 employees and relies on a modern and efficient company structure. The company’s personnel include top scientists and professionals with the necessary credentials and experience to implement the company’s target and promote its vision.

With a turnover of 267 million Euros in 2009, Boehringer Ingelheim Ellas Single Member SA is currently ranking 10th in the Greek pharmaceutical market in terms of sales with 2,7% market share.

General Manager of Boehringer Ingelheim Ellas Single Member SA is Mr. Dimitris Anagnostakis.


Skip to content